Form 4 for SPRO Spero Therapeutics, Inc.
Accepted 2023-02-03 00:00:00 ET · period of report 2023-02-01 · accession 0000899243-23-003945 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-02-03 | 2023-02-02 | SPRO | Shukla Sath | CFO | S - Sale | $1.83 | -9,504 | 312.5K | -3% | -$17.4K | |
| 2023-02-03 | 2023-02-01 | SPRO | Shukla Sath | CFO | A - Grant | $0.00 | +266.0K | 322.0K | +474% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-02-02 | S | D | 9,504 | $1.83 | 312,517 | D | — | — | (F4) Represents the weighted average sales price per share. The shares sold at prices ranging from $1.81 to $1.86 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. (F2) Includes 312,518 RSUs held by the Reporting Person. |
| 2 | Common | Common Stock | 2023-02-01 | A | A | 265,957 | $0.00 | 322,021 | D | — | — | (F1) Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in four equal annual installments beginning on February 1, 2024, subject to the Reporting Person's continued service through the applicable vesting date. (F2) Includes 312,518 RSUs held by the Reporting Person. |